Effects of insulin degludec and insulin glargine on day-to-day fasting plasma glucose variability in individuals with type 1 diabetes: a multicentre, randomised, crossover study

Diabetologia

Volumn 58, Issue 9, 2015, Pages 2013-2019

  Nakamura, Tomoaki ^a   Sakaguchi, Kazuhiko ^a   So, Anna ^a   Nakajima, Shinsuke ^a   Takabe, Michinori ^b   Komada, Hisako ^a   Okuno, Yoko ^a   Hirota, Yushi ^a   Nakamura, Takehiro ^c   Iida, Keiji ^d   Kajikawa, Michiko ^e   Nagata, Masao ^f   Ogawa, Wataru ^a   Seino, Susumu ^a  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Shinsuma General Hospital   (Japan)

^c KOBE CITY MEDICAL CENTER WEST HOSPITAL   (Japan)

^d Department of Surgery   (Japan)

^e YODOGAWA CHRISTIAN HOSPITAL   (Japan)

^f Kakogawa West City Hospital   (Japan)

Author keywords

Basal bolus insulin therapy; Day to day fasting plasma glucose variability; Insulin degludec; Insulin glargine; Type 1 diabetes

Indexed keywords

ALBUMIN; C PEPTIDE; GLUCOSE; GLYCOALBUMIN; INSULIN DEGLUDEC; INSULIN GLARGINE; UNCLASSIFIED DRUG; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; HUMAN INSULIN; INSULIN; LONG ACTING INSULIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; KIDNEY DYSFUNCTION; LIVER DYSFUNCTION; MALE; MULTICENTER STUDY; OUTPATIENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; AGED; ANALYSIS; BLOOD; CHEMISTRY; CLINICAL TRIAL; COMPLICATION; DIABETES MELLITUS, TYPE 1; MIDDLE AGED; REPRODUCIBILITY; SECRETION (PROCESS);

ADULT; AGED; BLOOD GLUCOSE; C-PEPTIDE; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 1; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN GLARGINE; INSULIN, LONG-ACTING; INSULIN, REGULAR, HUMAN; MALE; MIDDLE AGED; REPRODUCIBILITY OF RESULTS;

EID: 84938744828     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-015-3648-y     Document Type: Article

References (19)

1. Lepore M, Pampanelli S, Fanelli C et al (2000) Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes 49:2142–2148
2. Raskin P, Klaff L, Bergenstal R, Hallé JP, Donley D, Mecca T (2000) A 16-week comparison of the novel insulin analog insulin glargine (HOE 901) and NPH human insulin used with insulin lispro in patients with type 1 diabetes. Diabetes Care 23:1666–1671
3. Rossetti P, Pampanelli S, Fanelli C et al (2003) Intensive replacement of basal insulin in patients with type 1 diabetes given rapid-acting insulin analog at mealtime. Diabetes Care 26:1490–1496
4. Pieber TR, Eugène-Jolchine I, Derobert E (2000) Efficacy and safety of HOE 901 versus NPH insulin in patients with type 1 diabetes. The European Study Group of HOE 901 in Type 1 Diabetes. Diabetes Care 23:157–162
5. Ratner RE, Hirsch IB, Neifing JL, Garg SK, Mecca TE, Wilson CA (2000) Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. U.S. Study Group of Insulin Glargine in Type 1 Diabetes. Diabetes Care 23:639–643
6. Porcellati F, Rossetti P, Pampanelli S et al (2004) Better long-term glycaemic control with the basal insulin glargine as compared with NPH in patients with type 1 diabetes mellitus given meal-time lispro insulin. Diabet Med 21:1213–1220
7. Fulcher GR, Gilbert RE, Yue DK (2005) Glargine is superior to neutral protamine Hagedorn for improving glycated haemoglobin and fasting blood glucose levels during intensive insulin therapy. Intern Med J 35:536–542
8. Rosenstock J, Park G, Zimmerman J, U.S. Insulin Glargine (HOE 901) Type 1 Diabetes Investigator Group (2000) Basal insulin glargine (HOE 901) versus NPH insulin in patients with type 1 diabetes on multiple daily insulin regiments. U.S. Insulin Glargine (HOE 901) Type 1 Diabetes Investigator Group. Diabetes Care 23:1137–1142
9. Chatterjee S, Jarvis-Kay J, Rengarajan T, Lawrence IG, McNally PG, Davies MJ (2007) Glargine versus NPH insulin: efficacy in comparison with insulin aspart in a basal bolus regimen in type 1 diabetes—the glargine and aspart study (GLASS) a randomised cross-over study. Diabetes Res Clin Pract 77:215–222
10. Heise T, Nosek L, Bøttcher SG, Hastrup H, Haahr H (2012) Ultra-long-acting insulin degludec has a flat and stable glucose-lowering effect in type 2 diabetes. Diabetes Obes Metab 14:944–950
11. Jonassen I, Havelund S, Hoeg-Jensen T, Steensgaard DB, Wahlund PO, Ribel U (2012) Design of the novel protraction mechanism of insulin degludec, an ultra-long-acting basal insulin. Pharm Res 29:2104–2114
12. Birkeland KI, Home PD, Wendisch U et al (2011) Insulin degludec in type 1 diabetes: a randomized controlled trial of a new-generation ultra-long-acting insulin compared with insulin glargine. Diabetes Care 34:661–665
13. Heller S, Buse J, Fisher M et al (2012) Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. Lancet 379:1489–1497
14. Bode BW, Buse JB, Fisher M et al (2013) Insulin degludec improves glycaemic control with lower nocturnal hypoglycaemia risk than insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN® Basal-Bolus Type 1): 2-year results of a randomized clinical trial. Diabet Med 30:1293–1297
15. Niskanen L, Virkamäki A, Hansen JB, Saukkonen T (2009) Fasting plasma glucose variability as a marker of nocturnal hypoglycemia in diabetes: evidence from the PREDICTIVE study. Diabetes Res Clin Pract 86:e15–e18
16. Heise T, Hermanski L, Nosek L, Feldman A, Rasmussen S, Haahr H (2012) Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes. Diabetes Obes Metab 14:859–864
17. Rodbard D (2009) New and improved methods to characterize glycemic variability using continuous glucose monitoring. Diabetes Technol Ther 11:551–565
18. Nakamura T, Hirota Y, Hashimoto N et al (2014) Diurnal variation of carbohydrate insulin ratio in adult type 1 diabetic patients treated with continuous subcutaneous insulin infusion. J Diabetes Investig 5:48–50
19. Kuroda A, Kaneto H, Yasuda T et al (2011) Basal insulin requirement is ∼30% of the total daily insulin dose in type 1 diabetic patients who use the insulin pump. Diabetes Care 34:1089–1090